Compliance with anticoagulation guidelines following heart valve surgery: Lessons from four cycles of audit  by Patel, A. et al.
Abstracts / International Journal of Surgery 36 (2016) S31eS132 S55estimates for freedom from moderate or severe AR (censored for death/
heart transplant) were 85% (1 year), 71% (2 years) and 52% (3 and 4
years).
Conclusion: Increasing AR occurred during HVAD support despite avoid-
ance strategies. Concomitant bioprosthetic AVR should be considered at
implant if there is greater than mild AR and the expected duration of LVAD
support is long.http://dx.doi.org/10.1016/j.ijsu.2016.08.122
0461: COMPLIANCE WITH ANTICOAGULATION GUIDELINES FOLLOWING
HEART VALVE SURGERY: LESSONS FROM FOUR CYCLES OF AUDIT
A. Patel 1, N. Drury 1, J. McNamara 2,*, D. Pagano 1. 1Department of
Cardiothoracic Surgery, Queen Elizabeth Hospital., Birmingham, UK;
2University of Birmingham, Birmingham, UK.
Aim: Following heart valve surgery, patients often require long-term
treatment with anticoagulation therapy; local evidence-based guidelines
were developed for postoperative management. Several audit cycles have
been completed to assess and improve compliance with these guidelines.
Method: Data was retrospectively collected from the local PATS database
for the last consecutive 210 patients undergoing valve surgery. The stan-
dard was 100% compliance with the guidelines. Data from this audit cycle
was compared with the previous three cycles.
Result: First cycle (2009): 80% of patients were treated according to the
guidelines; recommended guidelines emphasised in the doctors' induc-
tion. Second cycle (2010): 90% according to the guidelines; recom-
mended incorporating a drop-down box into the electronic discharge
and displaying a guidelines poster in the doctors' ofﬁce. Third cycle
(2012): 81% according to the guidelines. Fourth cycle (2015): 69% ac-
cording to the guidelines. Adherence was lowest in patients who had
undergone mitral valve repair (36%) due to alternative use of antiplatelet
agents.
Conclusion: Previous audit cycle implementations improved compliance
with local guidelines but there is now signiﬁcant deviation. The use of
antiplatelet agents after mitral valve repair is now recommended in the
latest AHA/ACC guidance (2014) and differs from our current local guide-
lines which now require updating.http://dx.doi.org/10.1016/j.ijsu.2016.08.123
0486: A COMPARISON OF TRANSCATHETER AORTIC VALVE IMPLANTA-
TION AGAINST CONVENTIONAL THERAPIES IN THE TREATMENT OF SE-
VERE AORTIC STENOSIS IN RISK PATIENTS
A. Aftab. University of Nottingham, Nottingham, UK.
Aim: The present literature review aims to explore and compare the
application of transcatheter aortic valve replacement (TAVI) against con-
ventional therapies in the treatment of severe aortic stenosis (AS) in pa-
tients of varying operative risk.
Method: An electronic search was performed on 4 databases to identify
comparative studies on TAVI vs. conventional therapies. All-cause mor-
tality was the primary outcome. Procedural outcomes such as stroke,
vascular complications and major bleeding were determined as secondary
outcomes.
Result: 17 pertinent studies were included. TAVI signiﬁcantly reduced all-
cause mortality at all time points over follow-up compared with standard
therapy in inoperable patients, although it was associated with increased
vascular complications and stroke. All-cause mortality was comparable
between TAVI and surgical aortic valve replacement (SAVR) in high-risk
and lower than high-risk patients. Quality-of-life data demonstrated the
superiority of TAVI over standard therapy in inoperable patients; it showed
no signiﬁcant difference between TAVI and SAVR.
Conclusion: For the treatment of severe AS, TAVI may be recognised as an
effective alternative to standard therapy for inoperable patients. TAVI hasalso established itself as an effective intervention in high-risk and lower
than high-risk patients with outcomes comparable with SAVR.http://dx.doi.org/10.1016/j.ijsu.2016.08.124
0495: APROTININ FOR REDUCTION OF POST-OPERATIVE BLOOD LOSS
AND INCIDENCES OF CEREBROVASCULAR EVENTS FOLLOWING ENDO-
CARDITIS SURGERY. A PILOT STUDY
R. Karsan*, C. Rajakaruna. University of Bristol, Bristol, UK.
Aprotinin has shown to be efﬁcacious in cardiac surgeries involving high
blood loss. There is strong evidence indicating it effectively reduces post-
operative blood loss and the need for blood transfusion following surgery.
Evidence is however, limited in relation to the potential beneﬁts/risks of
aprotinin in open-heart endocarditis surgery.
Aim: To determine whether aprotinin reduces post-operative bleeding
following endocarditis surgery, compared to conventional techniques.
Method: In this retrospective study, data from 50 patients who underwent
endocarditis surgery from 2011-15, was analysed comparing 24-hour post-
operative blood loss, kidney function and cerebrovascular events. Com-
parisons of aprotinin vs. control (tranexamic acid) were undertaken with;
paired t-test, Mann-Whitney U test, Kruskal-Wallis test and Chi-squared
analysis.
Result: Blood loss over 24 hours was found to be lower in the group given
aprotinin, with a signiﬁcant difference seen at 6 and 12 hours post-
operatively (p¼0.03). The need for blood transfusion was also seen to be
lower in the aprotinin arm (RR ¼ 0.875, 95% CI ¼ 0.55-1.38 p ¼ 0.09).
Conclusion: This pilot study highlights potential beneﬁts of aprotinin to
reduce post-operative blood loss and transfusion requirement in endo-
carditis surgery, This is only a snapshot but suggests that the study
methodology employed is viable to a much larger study with increased
power.http://dx.doi.org/10.1016/j.ijsu.2016.08.125
0834: CLINICAL CASE FOCUSING ON CARDIAC IMAGING AND TUMOUR
CHARACTERISATION OF A CARDIAC PAPILLARY FIBROELASTOMA
C. Rees*, A. Brazier, F. Sogliani. Manchester Royal Inﬁrmary, Manchester, UK.
Background: Cardiac papillary ﬁbroelastoma (CPF) is a rare cardiac
tumour. Although non-malignant, these tumours can cause signiﬁcant
morbidity and even death through embolization andmass effects. Previous
meta-analysis has advocated surgical intervention in those with highly
mobile or symptomatic tumours. Assessing mobility of cardiac structures
requires clear and accurate imaging, of which multiple modes are avail-
able. This paper presents a case of CPF with a focus on cardiac imaging and
tumour characterization.
Case: A 74 year old gentlemanwas referred by his general practitioner for a
transthoracic echogardiogram because of severe hypertension. This
revealed a 1cm mass in the left ventricle. Further imaging was performed
including transoesophageal echocardiogram and cardiac magnetic reso-
nance imaging. This characterised the mass as a highly mobile CPF. Despite
the lack of symptoms that could be attributed to the tumour, it was excised
on the grounds of high thromboembolic risk. This was done on an elective
outpatient basis and he made a straightforward recovery.
Discussion: Primary cardiac tumours have an incidence of approximately
0.02%. Unlike the more common cardiac myxoma, the case for surgical
resection of CPF is less clear cut. In our case the decision to excise the
tumour was made on the grounds of tumour mobility.http://dx.doi.org/10.1016/j.ijsu.2016.08.126
